ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

REMODULIN
Pulmonary hypertension
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

REMODULIN Rx

Generic Name and Formulations:
Treprostinil 1mg/mL, 2.5mg/mL, 5mg/mL, 10mg/mL; soln for SC or IV continuous infusion.

Company:
United Therapeutics Corp.

Therapeutic Use:

Indications for REMODULIN:

Pulmonary arterial hypertension (PAH) in patients with NYHA Class II–IV symptoms, to diminish symptoms associated with exercise. PAH patients requiring transition from Flolan (epoprostenol), to reduce the rate of clinical deterioration.

Adult:

>16yrs: Give preferably by SC infusion; if not tolerated, may give by IV infusion (dilution required). Treatment-naïve: Initially 1.25ng/kg/min (or 0.625ng/kg/min, if not tolerated); may increase dose based on response by increments of 1.25ng/kg/min per week for 1st 4 weeks of treatment, then 2.5ng/kg/min per week. Doses >40ng/kg/min: limited experience. Mild-to-moderate hepatic insufficiency: initially 0.625ng/kg/min; increase cautiously. Severe hepatic insufficiency: not studied. Transition from Flolan (epoprostenol): increase treprostinil dose gradually as the epoprostenol dose is decreased, based on response; see full labeling.

Children:

≤16yrs: not recommended.

Warnings/Precautions:

Should be administered by experienced clinicians in PAH diagnosis and treatment. IV route: risk of blood stream infections and sepsis; may be fatal. Avoid abrupt withdrawal or sudden large dose reduction. Hepatic or renal insufficiency; titrate gradually. Elderly. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.

Interactions:

Increased risk of symptomatic hypotension with concomitant diuretics, antihypertensives, other vasodilators. May be potentiated by CYP2C8 inhibitor (eg, gemfibrozil). May be antagonized by CYP2C8 inducer (eg, rifampin). Increased risk of bleeding with anticoagulants.

Pharmacological Class:

Prostacyclin analogue.

Adverse Reactions:

Infusion reactions/site pain, headache, diarrhea, nausea, jaw pain, vasodilatation, dizziness, edema, pruritus, hypotension.

How Supplied:

Multidose vials (20mL)—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs